Amylin Pharma (AMLN) Posts Q3 GAAP Loss of $0.35; Revs Light

November 4, 2010 4:13 PM EDT
Get Alerts AMLN Hot Sheet
Trade AMLN Now!
Join SI Premium – FREE
Amylin Pharmaceuticals (Nasdaq: AMLN) reports Q3 GAAP loss of $0.35, which may not compare to the analyst estimate of ($0.35). Revenue for the quarter was $156.1 million, which compares to the estimate of $157.65 million.

Q3 loss ex-charge of $6 million.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories


Add Your Comment